AIMS: Chlorophyllin (CHLN), a synthetic derivative of chlorophyll, was assayed in the replication of poliovirus (PV-1) and bovine herpesvirus (BoHV-1) in HEp-2 cell cultures. METHODS AND RESULTS: Virucidal activity of CHLN was evaluated and the time-of-addition assay was performed as follows: before the infection (-1 and -2 h), at the time of the infection (0 h) and after the infection (1 and 2 h). Plaque reduction assay (PRA) showed that CHLN inhibited BoHV-1 and PV-1 infection and the 50% inhibitory concentrations (IC(50)) against BoHV-1 and PV-1 infection were 8.6 and 19.8 microg ml(-1), respectively. The time-of-addition study demonstrated that the CHLN was effective inhibiting viral replication in 51% and 66.5% for PV-1 and BoHV-1, respectively, at the highest concentration of 20.0 microg ml(-1), when added during the infection. The directed effect of CHLN on viral strains demonstrated an inhibition of 62% and 66.4% for PV-1 and BoHV-1, respectively, by PRA. CONCLUSIONS: These results demonstrated that CHLN could be used as an antiviral suggesting directed activity on virus particles and on virus-receptor sites to BoHV. For poliovirus, CHLN also demonstrated virucide activity, moreover, showed to inhibit early steps of the replication cycle. SIGNIFICANCE AND IMPACT OF THE STUDY: CHLN demonstrated promising selectivity index for both virus strains; therefore, it can be used for the development of an antiviral agent.
AIMS: Chlorophyllin (CHLN), a synthetic derivative of chlorophyll, was assayed in the replication of poliovirus (PV-1) and bovineherpesvirus (BoHV-1) in HEp-2 cell cultures. METHODS AND RESULTS: Virucidal activity of CHLN was evaluated and the time-of-addition assay was performed as follows: before the infection (-1 and -2 h), at the time of the infection (0 h) and after the infection (1 and 2 h). Plaque reduction assay (PRA) showed that CHLN inhibited BoHV-1 and PV-1 infection and the 50% inhibitory concentrations (IC(50)) against BoHV-1 and PV-1 infection were 8.6 and 19.8 microg ml(-1), respectively. The time-of-addition study demonstrated that the CHLN was effective inhibiting viral replication in 51% and 66.5% for PV-1 and BoHV-1, respectively, at the highest concentration of 20.0 microg ml(-1), when added during the infection. The directed effect of CHLN on viral strains demonstrated an inhibition of 62% and 66.4% for PV-1 and BoHV-1, respectively, by PRA. CONCLUSIONS: These results demonstrated that CHLN could be used as an antiviral suggesting directed activity on virus particles and on virus-receptor sites to BoHV. For poliovirus, CHLN also demonstrated virucide activity, moreover, showed to inhibit early steps of the replication cycle. SIGNIFICANCE AND IMPACT OF THE STUDY: CHLN demonstrated promising selectivity index for both virus strains; therefore, it can be used for the development of an antiviral agent.
Authors: Christine Cruz-Oliveira; Andreza F Almeida; João M Freire; Marjolly B Caruso; Maria A Morando; Vivian N S Ferreira; Iranaia Assunção-Miranda; Andre M O Gomes; Miguel A R B Castanho; Andrea T Da Poian Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Maria G Onyango; Geoffrey M Attardo; Erin Taylor Kelly; Sean M Bialosuknia; Jessica Stout; Elyse Banker; Lili Kuo; Alexander T Ciota; Laura D Kramer Journal: Front Microbiol Date: 2020-10-02 Impact factor: 5.640